[Articles] VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos
VRON-0200 alone or with investigational antiviral agents had no observed safety concerns and was well tolerated. Despite not targeting HBsAg, a single VRON-0200 dose induced broad and sustained anti-HBV immunity in most participants. When combined with antivirals, rapid and profo
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.